Literature DB >> 26258323

Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.

Vatche G Agopian1, Maud M Morshedi, Justin McWilliams, Michael P Harlander-Locke, Daniela Markovic, Ali Zarrinpar, Fady M Kaldas, Douglas G Farmer, Hasan Yersiz, Jonathan R Hiatt, Ronald W Busuttil.   

Abstract

OBJECTIVES: To evaluate the rate, effect, and predictive factors of a complete pathologic response (cPR) in patients with hepatocellular carcinoma (HCC) undergoing locoregional therapy (LRT) before liver transplantation (LT).
BACKGROUND: Eligible patients with HCC receive equal model for end-stage liver disease prioritization, despite variable risks of tumor progression, waitlist dropout, and posttransplant recurrence. Pretransplant LRT mitigates these risks by inducing tumor necrosis.
METHODS: Comparisons were made among HCC recipients with cPR (n = 126) and without cPR (n = 375) receiving pre-LT LRT (1994-2013). Multivariable predictors of cPR were identified.
RESULTS: Of 501 patients, 272, 148, and 81 received 1, 2, and 3 or more LRT treatments. The overall, recurrence-free, and disease-specific survival at 1-, 3-, and 5 years was 86%, 71%, 63%; 84%, 67%, 60%; and 97%, 90%, 87%. Compared with recipients without cPR, cPR patients had significantly lower laboratory model for end-stage liver disease scores, pretransplant alpha fetoprotein, and cumulative tumor diameters; were more likely to have 1 lesion, tumors within Milan/University of California, San Francisco (UCSF) criteria, LRT that included ablation, and a favorable tumor response to LRT; and had superior 1-, 3-, and 5-year recurrence-free survival (92%, 79%, and 73% vs 81%, 63%, and 56%; P = 0.006) and disease-specific survival (100%, 100%, and 99% vs 96%, 89%, and 86%; P < 0.001) with only 1 cancer-specific death and fewer recurrences (2.4% vs 15.2%; P < 0.001). Multivariate predictors of cPR included a favorable post-LRT radiologic/alpha fetoprotein tumor response, longer time interval from LRT to LT, and lower model for end-stage liver disease score and maximum tumor diameter (C-statistic 0.75).
CONCLUSIONS: Achieving cPR in patients with HCC receiving LRT strongly predicts tumor-free survival. Factors predicting cPR are identified, allowing for differential prioritization of HCC recipients based on their variable risks of post-LT recurrence. Improving LRT strategies to maximize cPR would enhance posttransplant cancer outcomes.

Entities:  

Mesh:

Year:  2015        PMID: 26258323     DOI: 10.1097/SLA.0000000000001384

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  43 in total

1.  Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria.

Authors:  Victor M Zaydfudim; Neeta Vachharajani; Goran B Klintmalm; William R Jarnagin; Alan W Hemming; Maria B Majella Doyle; Keith M Cavaness; William C Chapman; David M Nagorney
Journal:  Ann Surg       Date:  2016-10       Impact factor: 12.969

Review 2.  Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma.

Authors:  Samdeep K Mouli; Laura W Goff
Journal:  Curr Treat Options Oncol       Date:  2017-10-27

3.  Bridging to liver transplantation patients with a hepatocellular carcinoma within Milan criteria: how worth is it?

Authors:  Angelo Sangiovanni; Massimo Colombo
Journal:  Hepatobiliary Surg Nutr       Date:  2018-06       Impact factor: 7.293

4.  Loco-regional treatments on the liver transplant waiting list: unmasking hepatocellular carcinoma (HCC) biology.

Authors:  Amine Benmassaoud; Emmanuel A Tsochatzis
Journal:  Hepatobiliary Surg Nutr       Date:  2018-06       Impact factor: 7.293

Review 5.  Update on Embolization Therapies for Hepatocellular Carcinoma.

Authors:  Sirish Kishore; Tamir Friedman; David C Madoff
Journal:  Curr Oncol Rep       Date:  2017-06       Impact factor: 5.075

Review 6.  Bridging to liver transplantation in HCC patients.

Authors:  Dagmar Kollmann; Nazia Selzner; Markus Selzner
Journal:  Langenbecks Arch Surg       Date:  2017-07-28       Impact factor: 3.445

Review 7.  Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review.

Authors:  Dong-Wei Xu; Ping Wan; Qiang Xia
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

8.  Multicenter Study of Staging and Therapeutic Predictors of Hepatocellular Carcinoma Recurrence Following Transplantation.

Authors:  Theodore H Welling; Kevin Eddinger; Kristen Carrier; Danting Zhu; Tyler Kleaveland; Derek E Moore; Douglas E Schaubel; Peter L Abt
Journal:  Liver Transpl       Date:  2018-09       Impact factor: 5.799

9.  Stereotactic ablative radiation therapy prior to liver transplantation in hepatocellular carcinoma.

Authors:  Alessia Guarneri; Pierfrancesco Franco; Renato Romagnoli; Elisabetta Trino; Stefano Mirabella; Luca Molinaro; Giorgia Rizza; Andrea Riccardo Filippi; Patrizia Carucci; Mauro Salizzoni; Umberto Ricardi
Journal:  Radiol Med       Date:  2016-07-22       Impact factor: 3.469

Review 10.  Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun.

Authors:  Taizo Hibi; Osamu Itano; Masahiro Shinoda; Yuko Kitagawa
Journal:  Surg Today       Date:  2016-04-29       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.